PHRIXUS PHARMACEUTICALS, INC.

Address

1600 HURON PARKWAY BLDG. 520, 2ND FLOOR
ANN ARBOR, MI, 48109-5001

Information

DUNS: 620122676
# of Employees: 2

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188

    Amount: $622,877.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and ...

    SBIRPhase I2012Department of Health and Human Services
  2. Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo

    Amount: $583,225.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystr ...

    SBIRPhase I2011Department of Health and Human Services
  3. CREATION OF STANDARDS AND DEVELOPMENT OF MOLECULAR CLINICAL DIAGNOSTIC FOR ENTERI

    Amount: $153,916.00

    DESCRIPTION (provided by applicant): This one-year phase I SBIR proposal will apply the benefits of molecular testing, in terms of speed, sensitivity, and ultimately value, to diagnose enteric Microsp ...

    SBIRPhase I2010Department of Health and Human Services
  4. SBIR Phase I: Standardizing Microbial Water Quality Monitoring Using Synthetic Biology

    Amount: $101,684.00

    This SBIR Phase I project will develop positive controls based on existing genetic sequencing data to generate sufficient quantities of positive control DNA from whole organisms for PCR-based pathogen ...

    SBIRPhase I2010National Science Foundation
  5. Poloxamer 188 mechanism of action in ischemic heart failure.

    Amount: $306,708.00

    DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxyge ...

    STTRPhase I2010Department of Health and Human Services
  6. Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H

    Amount: $379,487.00

    DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and ...

    SBIRPhase I2009Department of Health and Human Services
  7. Real-time PCR Diagnostic Kit for Giardia and Cryptosporidium

    Amount: $958,924.00

    DESCRIPTION (provided by applicant): This two-year proposal seeks small business support for IDX Labs LLC to continue collaborating with Dr. Houpt at the University of Virginia to bring sensitive real ...

    STTRPhase II2008Department of Health and Human Services
  8. Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis

    Amount: $277,646.00

    DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement the ...

    SBIRPhase I2008Department of Health and Human Services
  9. Targeted DNA extraction for Tuberculosis PCR from sputum

    Amount: $275,497.00

    DESCRIPTION (provided by applicant): Present diagnostic methods for active Tuberculosis are inadequate. Acid fast staining and microscopy of sputum is insensitive, particularly in advanced AIDS when a ...

    STTRPhase I2007Department of Health and Human Services
  10. Chronic Treatment of Heart Failure With Poloxamer-188

    Amount: $215,084.00

    DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of ...

    SBIRPhase I2007Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government